Profile data is unavailable for this security.
About the company
Zhejiang Shapuaisi Pharmaceutical Co Ltd is a China-based company principally engaged in the research and development, production and sales of pharmaceutical, and the provision of medical services. The Company primarily operates its businesses through two segments. The Commodity Sales segment mainly covers the treatment fields of ophthalmic drugs (anti-cataract drugs), and antimicrobial drugs (cephalosporins, quinolones), and main products include benzalkonium chloride eye drops, cefixime products and other products. The Diagnosis and Treatment Service segment mainly provides ophthalmic specialty medical services, and provides medical services through the gynecology, obstetrics, pediatrics and other medical and technical departments of obstetrics and gynecology hospitals. The Company mainly conducts its businesses in the domestic market.
- Revenue in CNY (TTM)475.19m
- Net income in CNY-65.05m
- Incorporated2000
- Employees1.33k
- LocationZhejiang Shapuaisi Pharmaceutical Co LtdLumianjin BridgeChengbei Road, Pinghu CityJIAXING 314200ChinaCHN
- Phone+86 57 385021168
- Fax+86 57 385076188
- Websitehttp://www.zjspas.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hainan Huluwa Pharmaceutical Grop Co Ltd | 902.48m | -369.56m | 2.70bn | 2.10k | -- | 3.91 | -- | 2.99 | -0.9236 | -0.9236 | 2.26 | 1.72 | 0.3055 | 1.74 | 1.60 | 429,141.60 | -12.36 | 0.2178 | -22.13 | 0.3739 | 31.53 | 54.80 | -40.47 | 0.3213 | 0.5566 | -6.97 | 0.6414 | 700.10 | -21.26 | 1.60 | -2,629.23 | -- | 21.75 | -- |
| Zhejiang Shapuaisi Pharmaceutical Co Ltd | 475.19m | -65.05m | 2.76bn | 1.33k | -- | 1.71 | -- | 5.81 | -0.1796 | -0.1796 | 1.27 | 4.31 | 0.2236 | 2.35 | 14.31 | 357,822.00 | -3.08 | -2.12 | -3.66 | -2.49 | 50.11 | 55.38 | -13.78 | -7.33 | 0.8289 | -0.9506 | 0.1587 | -- | -24.96 | -1.27 | -585.85 | -- | 44.50 | -- |
| Shanghai Serum Bio-Technology Co Ltd | 196.76m | 45.55m | 2.83bn | 326.00 | 62.19 | 2.52 | -- | 14.40 | 0.4209 | 0.4209 | 1.82 | 10.40 | 0.1706 | 1.22 | 3.20 | 603,567.30 | 3.95 | 7.64 | 4.04 | 7.87 | 76.68 | 78.94 | 23.15 | 30.08 | 27.50 | -- | 0.0035 | 77.34 | 2.51 | 0.7147 | 14.23 | -7.60 | 18.77 | -- |
| Hanshang Group Co Ltd | 1.04bn | -7.75m | 2.86bn | 2.24k | -- | 1.71 | -- | 2.76 | -0.0263 | -0.0263 | 3.51 | 5.66 | 0.2992 | 2.45 | 8.58 | 463,254.10 | -0.5073 | 1.38 | -0.911 | 2.59 | 44.80 | 61.66 | -1.70 | 3.79 | 0.3006 | -0.0194 | 0.300 | 17.52 | -15.41 | 0.3108 | -123.83 | -- | 4.52 | -- |
| Ginwa Enterprise Group Inc | 550.44m | 78.32m | 2.96bn | 588.00 | 36.71 | 1.87 | -- | 5.37 | 0.2157 | 0.2157 | 1.54 | 4.24 | 0.2885 | 4.56 | 4.97 | 936,120.60 | 4.04 | 0.839 | 4.86 | 0.9762 | 76.30 | 75.14 | 14.00 | 2.83 | 1.84 | -- | 0.0561 | 52.12 | 3.55 | -4.95 | 273.96 | 23.56 | 28.32 | 0.00 |
| Holder | Shares | % Held |
|---|---|---|
| Golden Trust Sinopac Fund Management Co., Ltd.as of 30 Jun 2025 | 3.90m | 1.31% |
| Goldstate Capital Fund Management Co., Ltd.as of 30 Jun 2025 | 1.40m | 0.47% |
| Gfund Management Co., Ltd.as of 30 Jun 2025 | 352.30k | 0.12% |
| Huatai-PineBridge Fund Management Co., Ltd.as of 30 Jun 2025 | 203.90k | 0.07% |
| Shanghai Guotai Junan Securities Assets Management Co., Ltd.as of 30 Jun 2025 | 77.20k | 0.03% |
| Zhong Ou Asset Management Co., Ltdas of 30 Jun 2025 | 48.70k | 0.02% |
| Western Leadbank Fund Management Co., Ltdas of 30 Jun 2025 | 42.00k | 0.01% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2025 | 18.00k | 0.01% |
| Hongde Fund Management Co., Ltd.as of 30 Jun 2025 | 12.00k | 0.00% |
| E Fund Management Co., Ltd.as of 30 Jun 2025 | 10.40k | 0.00% |
